Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review

References

• de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49(2):256–261. doi:10.1038/ng.3760
   PubMed Web of Science ®Google Scholar
• Gastroenterological Society of Australia (GESA). Clinical Update for General Practitioners and Physicians - Inflammatory Bowel Disease. GESA; 2018.
   Google Scholar
• Aluzaite K, Al-Mandhari R, Osborne H, et al. Detailed multi-dimensional assessment of fatigue in inflammatory bowel disease. Inflamm Intest Dis. 2019;3(4):192–201. doi:10.1159/000496054
   PubMedGoogle Scholar
• Feldman PA, Wolfson D, Barkin JS. Medical management of Crohn’s disease. Clin Colon Rectal Surg. 2007;20(4):269–281. doi:10.1055/s-2007-991026
   PubMedGoogle Scholar
• Amiesimaka OI, Braund R, Aluzaite K, Schultz M. Constraints on medication-based inflammatory bowel disease therapy in Aotearoa New Zealand - why medication adherence is important. NZ Med J. 2023;136(1574):82–89.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Abreu MT, Achkar JP, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2–25; quiz S26. doi:10.1038/ajg.2011.58
   PubMed Web of Science ®Google Scholar
• Hanzel J, Hulshoff MS, Grootjans J, D’Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18(5):513–524. doi:10.1080/1744666X.2022.2069562
   PubMed Web of Science ®Google Scholar
• Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127–142. doi:10.1016/j.tips.2016.10.014
   PubMed Web of Science ®Google Scholar
• Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. doi:10.1111/jcpt.12830
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi:10.1111/j.1365-2125.2012.04167.x
   PubMed Web of Science ®Google Scholar
• Tae CH, Jung S-A, Moon HS, et al. Importance of patients’ knowledge of their prescribed medication in improving treatment adherence in inflammatory bowel disease. J Clin Gastroenterol. 2016;50(2):157–162. doi:10.1097/MCG.0000000000000431
   PubMed Web of Science ®Google Scholar
• Samson CM, Mager D, Frazee S, Yu F. Remission in pediatric inflammatory bowel disease correlates with prescription refill adherence rates. J Pediatr Gastroenterol Nutr. 2017;64(4):575–579. doi:10.1097/MPG.0000000000001304
   PubMed Web of Science ®Google Scholar
• Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100. doi:10.3389/fphar.2017.00100
   PubMed Web of Science ®Google Scholar
• Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2199–2206. doi:10.1097/MIB.0b013e31829ed8a6
   PubMed Web of Science ®Google Scholar
• Severs M, Mangen MJ, Fidder HH, et al. Clinical predictors of future nonadherence in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(9):1568–1576. doi:10.1097/MIB.0000000000001201
   PubMed Web of Science ®Google Scholar
• Aluzaite K, Braund R, Seeley L, Amiesimaka OI, Schultz M. Adherence to inflammatory bowel disease medications in Southern New Zealand. Crohns Colitis 360. 2021;3(3). doi:10.1093/crocol/otab056
   PubMedGoogle Scholar
• Pellegrino R, Pellino G, Selvaggi F, Federico A, Romano M, Gravina AG. Therapeutic adherence recorded in the outpatient follow-up of inflammatory bowel diseases in a referral center: damages of COVID-19. Dig Liver Dis. 2022;54(10):1449–1451. doi:10.1016/j.dld.2022.07.016
   PubMedGoogle Scholar
• van der Have M, Oldenburg B, Kaptein AA, et al. Non-adherence to Anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis. 2016;10(5):549–555. doi:10.1093/ecco-jcc/jjw002
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence. London: NICE; 2009.
   Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/217047
   PubMed Web of Science ®Google Scholar
• World Health Organisation (WHO). Adherence to Long-Term Therapies: Evidence for Action. Geneva: WHO; 2003.
   Google Scholar
• Brown MT, Bussell J, Dutta S, Davis K, Strong S, Mathew S. Medication adherence: truth and consequences. Am J Med Sci. 2016;351(4):387–399. doi:10.1016/j.amjms.2016.01.010
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Sooronbaev T, Akylbekov A, et al. Medication availability and economic barriers to adherence in asthma and COPD patients in low-resource settings. NPJ Prim Care Respir Med. 2022;32(1):20. doi:10.1038/s41533-022-00281-z
   PubMed Web of Science ®Google Scholar
• Khan R, Socha-Dietrich K. Investing in Medication Adherence Improves Health Outcomes and Health System Efficiency: Adherence to Medicines for Diabetes, Hypertension, and Hyperlipidaemia. Paris: OECD; 2018:18152015.
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. New Engl J Med. 2005;353(5):487–497. doi:10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Zullig LL, Gellad WF, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139–149. doi:10.2147/PPA.S69651
   PubMedGoogle Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States. Ann Internal Med. 2012;157(11):757–836. doi:10.7326/0003-4819-157-11-201212040-00538
   PubMed Web of Science ®Google Scholar
• Amiesimaka OI, Aluzaite K, Braund R, Schultz M. “It’s just like putting your socks on”: patients’ perspectives on inflammatory bowel disease medication adherence. Explor Res Clin Soc Pharm. 2023;12:100385.
   PubMedGoogle Scholar
• Pharmaceutical Management Agency (PHARMAC). Achieving Medicine Access Equity in Aotearoa New Zealand: Towards a Theory of Change. Wellington, New Zealand: PHARMAC; 2019.
   Google Scholar
• Bager P, Jäghult S. Adherence in inflammatory bowel disease (IBD): a clinical review. Gastrointestinal Nurs. 2019;17(6):24–27. doi:10.12968/gasn.2019.17.6.24
   Google Scholar
• Devlen J, Beusterien K, Yen L, Ahmed A, Chiefetz AS, Moss AC. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm. 2014;20(3):309–314. doi:10.18553/jmcp.2014.20.3.309
   PubMed Web of Science ®Google Scholar
• Wheat CL, Maass M, Devine B, Thornton T, Grembowski D, Ko CW. Educational needs of patients with inflammatory bowel disease IBD and nonadherence to medical therapy: a qualitative study. J Inflam Bowel Dis Disord. 2016;1(1):1000106.
   Google Scholar
• Broekman M, Coenen MJH, Wanten GJ, et al. Patients’ beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2018;30(2):167–173. doi:10.1097/MEG.0000000000001025
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Vernero M, Saracco GM, et al. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scand J Gastroenterol. 2018;53(2):141–146. doi:10.1080/00365521.2017.1405070
   PubMed Web of Science ®Google Scholar
• Amiesimaka OI, Braund R, Aluzaite K, Schultz M. Using electronic health records in analysing medication adherence in southern New Zealand patients with inflammatory bowel diseases. N Z Med J. 2024;137(1588):25–36. doi:10.26635/6965.6209
   PubMedGoogle Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028. doi:10.1007/s12325-015-0256-7
   PubMed Web of Science ®Google Scholar
• Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017;15(4):434–445. doi:10.5217/ir.2017.15.4.434
   PubMed Web of Science ®Google Scholar
• Greenley RN, Kunz JH, Walter J, Hommel KA. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1534–1545. doi:10.1097/MIB.0b013e3182813482
   PubMed Web of Science ®Google Scholar
• Ashok K, Mathew AA, Thomas A, Mohan D, Gopalakrishna R, Reghu R. Clinical Pharmacist’s Interventions on medication adherence and knowledge of inflammatory bowel disease patients. J Young Pharm. 2017;9(3):381–385. doi:10.5530/jyp.2017.9.76
   Google Scholar
• Tiao DK, Chan W, Jeganathan J, et al. Inflammatory bowel disease pharmacist adherence counseling improves medication adherence in crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2017;23(8):1257–1261. doi:10.1097/MIB.0000000000001194
   PubMed Web of Science ®Google Scholar
• Jeganathan J, Lee CH, Rahme A, et al. Pediatric-to-adult transition and medication adherence in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1065–1070. doi:10.1097/MIB.0000000000001114
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Schreiber S, Siegmund B, et al. Patient education in a 14-month randomised trial fails to improve adherence in ulcerative colitis: influence of demographic and clinical parameters on non-adherence. J Crohns Colitis. 2017;11(9):1052–1062. doi:10.1093/ecco-jcc/jjx062
   PubMed Web of Science ®Google Scholar
• Lofland JH, Johnson PT, Ingham MP, Rosemas SC, White JC, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence. 2017;11:947–958. doi:10.2147/PPA.S133222
   PubMed Web of Science ®Google Scholar
• Miloh T, Shub M, Montes R, Ingebo K, Silber G, Pasternak B. Text messaging effect on adherence in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(6):939–942. doi:10.1097/MPG.0000000000001399
   PubMed Web of Science ®Google Scholar
• Carlsen K, Jakobsen C, Houen G, et al. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: a randomized controlled trial. Inflamm Bowel Dis. 2017;23(3):357–365. doi:10.1097/MIB.0000000000001170
   PubMed Web of Science ®Google Scholar
• Gillespie D, Hood K, Farewell D, Stenson R, Probert C, Hawthorne AB. Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflamm Bowel Dis. 2014;20(1):82–91. doi:10.1097/01.MIB.0000437500.60546.2a
   PubMed Web of Science ®Google Scholar
• Park SK, Park SH, Eun CS, et al. Adherence to asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study. Intest Res. 2019;17(3):349–356. doi:10.5217/ir.2018.00064
   PubMed Web of Science ®Google Scholar
• Schultheiss JPD, Altena S, Clevers MR, Baas D, Jharap B, Fidder HH. Adherence to adalimumab was not improved by a reminder-based intervention with an electronic needle container. Dig Dis Sci. 2021;66(5):1477–1487. doi:10.1007/s10620-020-06395-z
   PubMed Web of Science ®Google Scholar
• Greenley RN, Gumidyala AP, Nguyen E, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflamm Bowel Dis. 2015;21(11):2649–2657. doi:10.1097/MIB.0000000000000530
   PubMed Web of Science ®Google Scholar
• Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20(12):2276–2285. doi:10.1097/MIB.0000000000000199
   PubMed Web of Science ®Google Scholar
• Del Hoyo J, Nos P, Faubel R, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. J Med Internet Res. 2018;20(11):e11602. doi:10.2196/11602
   PubMed Web of Science ®Google Scholar
• Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. J Manag Care Spec Pharm. 2019;25(7):770–779. doi:10.18553/jmcp.2019.18443
   PubMed Web of Science ®Google Scholar
• Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859–867. doi:10.18553/jmcp.2017.16272
   PubMedGoogle Scholar
• Maddux M, Ricks S, Delurgio S, Hommel K. A pilot study evaluating the impact of an adherence-promoting intervention among nonadherent youth with inflammatory bowel disease. J Pediatr Nurs. 2017;35:72–77. doi:10.1016/j.pedn.2017.03.006
   PubMed Web of Science ®Google Scholar
• Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised adherence support for maintenance treatment of inflammatory bowel disease: a tailored digital intervention to change adherence-related beliefs and barriers. J Crohns Colitis. 2020;14(10):1394–1404. doi:10.1093/ecco-jcc/jjz034
   PubMed Web of Science ®Google Scholar
• de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–968. doi:10.1016/S0140-6736(17)31327-2
   PubMed Web of Science ®Google Scholar
• Linn AJ, van Dijk L, van Weert JCM, Gebeyehu BG, van Bodegraven AA, Smit EG. Creating a synergy effect: a cluster randomized controlled trial testing the effect of a tailored multimedia intervention on patient outcomes. Patient Educ Couns. 2018;101(8):1419–1426. doi:10.1016/j.pec.2018.03.017
   PubMed Web of Science ®Google Scholar
• Arnet I, Greenland M, Knuiman MW, et al. Operationalization and validation of a novel method to calculate adherence to polypharmacy with refill data from the Australian pharmaceutical benefits scheme (PBS) database. Clin Epidemiol. 2018;10:1181–1194. doi:10.2147/CLEP.S153496
   PubMed Web of Science ®Google Scholar
• Kini V, Ho PM. Interventions to Improve Medication Adherence: a Review. JAMA. 2018;320(23):2461–2473. doi:10.1001/jama.2018.19271
   PubMed Web of Science ®Google Scholar
• de Jong M, van der Meulen-de Jong A, Romberg-Camps M, et al. Development and feasibility study of a telemedicine tool for all patients with IBD: myIBDcoach. Inflamm Bowel Dis. 2017;23(4):485–493. doi:10.1097/MIB.0000000000001034
   PubMed Web of Science ®Google Scholar
• Hunt MG, Loftus P, Accardo M, Keenan M, Cohen L, Osterman MT. Self-help cognitive behavioral therapy improves health-related quality of life for inflammatory bowel disease patients: a randomized controlled effectiveness trial. J Clin Psychol Med Settings. 2020;27(3):467–479. doi:10.1007/s10880-019-09621-7
   PubMed Web of Science ®Google Scholar
• Stapersma L, van den Brink G, van der Ende J, et al. Psychological outcomes of a cognitive behavioral therapy for youth with inflammatory bowel disease: results of the HAPPY-IBD randomized controlled trial at 6- and 12-month follow-up. J Clin Psychol Med Settings. 2020;27(3):490–506. doi:10.1007/s10880-019-09649-9
   PubMed Web of Science ®Google Scholar
• Gravina AG, Pellegrino R, Palladino G, et al. Targeting the gut-brain axis for therapeutic adherence in patients with inflammatory bowel disease: a review on the role of psychotherapy. Brain-Apparatus Commun. 2023;2(1):2181101.
   Google Scholar
• Ankersen DV, Carlsen K, Marker D, Munkholm P, Burisch J. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32(Suppl 1):27–31. doi:10.1111/jgh.13691
   PubMedGoogle Scholar
• George LA, Cross RK. Remote Monitoring and Telemedicine in IBD: are We There Yet? Curr Gastroenterol Rep. 2020;22(3):12. doi:10.1007/s11894-020-0751-0
   PubMedGoogle Scholar